Patent US4186316A successfully refreshed from Google Patents.
EP0104546A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Therapeutic dipeptides
Assignee: USV Pharmaceutical Corp
•
Filing: 1983-09-14
•
Granted: —
•
Expires: 2003-09-14
Abstract
Abstract This invention relates to new substituted dipeptides having angiotension converting enzyme inhibitory activity, pharmaceutical compositions thereof and processes for the production thereof.
Inventors
- 👤 John T. Suh
- 👤 Jeffrey N. Barton
- 👤 John R. Regan
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-29 21:24
CPC Classifications
C; C07; C07K; C07K5/00; C07K5/02; C07K5/022; C07K5/0222; A; A61; A61P; A61P43/00; A61P9/00; A61P9/12; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/80
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
413 words
-1. A compound of the formula wherein A and A' are independently hydroxy, lower alkoxy, lower alkenoxy, di-lower alkylamino, lower alkoxy, acylamino lower alkoxy, acyloxy lower alkoxy, aryloxy, aryl-lower alkyloxy, amino, lower alkylamino, di-lower alkylamino,aryl-lower alkylamino, hydroxyamino, or substituted aryloxy, or substituted aryl-lower alkoxy wherein the substituent is methyl, halo or methoxy; R 1 , R 2 , R 3 , R 4 and R 5 taken separately are each hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, fused aryl-cycloalkyl, aralkyl, cycloalkyl, heterocyclic, substituted alkyl, alkenyl, or alkynyl groups in which the substituents are hydroxy, alkoxy, halo, guanidino, amino, alkylamino, mercapto, or alkylmercapto, substituted cycloalkyl groups in which the substituents are alkyl, halo, haloalkyl, hydroxy, alkylamino, nitro or trifluoromethyl, and substituted aryl and heterocyclic groups in which the substituents are alkyl, hydroxy, alkoxy, hydroxyalkyl, halo, mercapto, alkylmercapto, mercaptoalkyl, haloalkyl, amino, alkylamino, aminoalkyl, nitro, methylenedioxy, or trifluoromethyl; R 1 and R 2 when taken together with the carbon and nitrogen to which they are respectively attached and R 2 and R 3 when taken together with the nitrogen and carbon to which they are respectively attached form an N-heterocyclic containing from 3 to 5 carbon atoms or 2 to 4 carbon atoms and a sulfur or nitrogen atom; M is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, polycycloalkyl, polycycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl-alkyl, hetero-cycloalkyl, hetero-cycloalkyl-alkyl, fused aryl-cycloalkyl, fused aryl-cycloalkyl-alkyl, fused heteroaryl-cycloalkyl, fused heteroaryl-cycloalkyl-alkyl, alkoxyalkyl, alkylthioalkyl, alkylaminoalkyl, dialkylaminoalkyl; M' is hydrogen, lower alkyl, cycloalkyl, phenyl, phenyl lower alkyl, hydroxy phenyl lower alkyl, hydroxy lower alkyl, amino lower alkyl, guanidino lower alkyl, imidazolyl lower alkyl, indolyl lower alkyl, mercapto lower alkyl or lower alkyl mercapto lower alkyl; M and M' when taken together form an alkylene bridge of from 2 to 5 carbon atoms; an alkylene bridge of from 2 to 5 carbon atoms and one sulfur atom; an alkylene bridge of from 3 to 4 carbon atoms containing a double bond; a substituted alkylene bridge containing from 2 to 5 carbon atoms in which the substituent is hydroxy, lower alkoxy, or lower alkyl; or fused aralkylene; M and M' when taken with the carbon and nitrogen to which they are respectively attached form a tetrahydroisoquinoline, dihydroindole or pyrrolidine ring; wherein n is 2, 3 or 4 and n' is 1, 2 or 3; X is or A r is arylene or substituted arylene containing one or two substituents H, halo, CF 3 , lower alkyl, OH , loweralkoxy, mercapto, amino or sulfamyl; and pharmaceutically-acceptable salts thereof.
Claim 2
Dependent Claim
373 words
2 . A compound of the formula: and pharmaceutically-acceptable salts thereof, wherein A and A' are independently hydroxy, lower alkoxy, lower alkenoxy, di-lower alkylamino, lower alkoxy, acylamino lower alkoxy, acyloxy lower alkoxy, aryloxy, aryl-lower alkyloxy, amino, lower alkylamino, di-lower alkylamino, aryl-lower alkylamino, hydroxyamino, or substituted aryloxy, or substituted aryl-lower alkoxy wherein the substituent is methyl, halo or methoxy; R 1 , R 2 , R 3 , R 4 and R 5 taken separately are each hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, fused aryl-cycloalkyl, aralkyl, cycloalkyl, heterocyclic, substituted alkyl, alkenyl, or alkynyl groups in which the substituents are hydroxy, alkoxy, halo, amino, alkylamino, thio, or alkylmercapto, substituted cycloalkyl groups in which the substituents are alkyl, halo, haloalkyl, hydroxy, alkyl- amino, nitro or trifluoromethyl, and substituted aryl and heterocyclic groups in which the substituents are alkyl, hydroxy, alkoxy, hydroxyalkyl, halo, mercapto, alkylmercapto, mercaptoalkyl, haloalkyl, amino, alkylamino, aminoalkyl, nitro, methylenedioxy, or trifluoromethyl; R1 and R 2 when taken together with the carbon and nitrogen to which they are respectively attached and R 2 and R 3 when taken together with the nitrogen and carbon to which they are respectively attached form an N-heterocyclic containing from 3 to 5 carbon atoms or 2 to 4 carbon atoms and a sulfur or nitrogen atom; M is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, polycycloalkyl, polycycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl-alkyl, hetero-cycloalkyl, hetero-cycloalkyl-alkyl, fused aryl-cycloalkyl, fused aryl-cycloalkyl-alkyl, fused heteroaryl-cycloalkyl, fused heteroaryl-cycloalkyl-alkyl, alkoxyalkyl, alkylthioalkyl, alkylaminoalkyl, dialkylaminoalkyl; M' is hydrogen, lower alkyl, cycloalkyl, phenyl, phenyl lower alkyl, hydroxy phenyl lower alkyl, hydroxy lower alkyl, amino lower alkyl, guanidino lower alkyl, imidazolyl lower alkyl, indolyl lower alkyl, mercapto lower alkyl or lower alkyl mercapto lower alkyl; M and M' when taken together form an alkylene bridge of from 2 to 5 carbon atoms; an alkylene bridge of from 2 to 5 carbon atoms and one sulfur atom; an alkylene bridge of from 3 to 4 carbon atoms containing a double bond; a substituted alkylene bridge containing from 2 to 5 carbon atoms in which the substituent is hydroxy, lower alkoxy, or lower alkyl; or fused aralkylene; and M and M' when taken with the carbon and nitrogen to which they are respectively attached form a tetrahydro- isoquinoline, dihydroindole or pyrrolidine ring.
Claim 3
Dependent Claim
11 words
The compound of claim 1 or claim 2 wherein X is
Claim 4
Dependent Claim
11 words
The compound of claim 1 or claim 2 wherein X is
Claim 5
Dependent Claim
12 words
The compound of claim 1 or claim 2 wherein X is 2-indanyl.
Claim 6
Dependent Claim
12 words
The compound of claim 1 or claim 2 wherein X is 1-indanyl.
Claim 7
Dependent Claim
31 words
The compound as in any of claims 1-6 which is one of the following: N-[1-Ethyoxycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-alanyl-proline. 2-N-[1-Ethoxycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid. N-[N-[1-ethoxy-carbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-alanyl]N-(2,3-Dihydro-lH-inden-5-yl)-glycine. N-[N-[1-ethoxycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-alanyl]N-Cyclopentyl-glycine. 1-N-[1-Ethoxycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-alanyl-2,3-dihydroindole-2-carboxylic acid. N-[(lS)-l-Ethoxycarbonyl-l-(2,3-dihydro-lH- inden-2-yl)-methyl]-L-alanyl-L-proline. (3S)-2-N-[(1S)-1-Ethoxycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-L-alanyl-1,2,3,4-tetrahydroisoquinoline -3-carboxylic acid. N-[N-[(1S)-1-ethoxycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-L-alanyl]N-(2,3-Dihydro-lH-inden-5-yl)-glycine. N-[N-[(lS)-i-ethoxycarbonyl-l-(2,3-dihydro-lH- inden-2-yl)-methyl]-L-alanyl]N-Cyclopentyl-glycine. (2S)-1-N-[(1S)-1-Ethoxycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-L-alanyl-2,3-dihydroindole-2-carboxylic acid.
Claim 8
Dependent Claim
20 words
8 . A therapeutic composition comprising a therapeutically-effective amount of at least one compound as in any of claims 1-7.
Claim 9
Dependent Claim
108 words
A process for the preparation of compounds of formula I herein which comprises: a) reacting under amide-forming conditions an amine of formula II herein whith an acylating derivative of an acid of formula III; b) reacting an amine of formula VI herein with a β-keto acid or ester of formula VII herein and reducing the resulting imine to obtain a compound of formula I in which R 3 and R 4 are hydrogen; or c) reacting a compound of formula VI herein with anα-halo acid or ester of formula VIII herein; and optionally forming salts of the resulting compounds, particularly pharmaceutically-acceptable salts, by reaction with acids or bases.
Claim 10
Dependent Claim
13 words
10 . The process of claim 9 wherein, in the product, X is
Claim 11
Dependent Claim
11 words
The process of claim 9 wherein, in the product, X is
Claim 12
Dependent Claim
12 words
The process of claim 9 wherein, in the product, X is 2-indanyl.
Claim 13
Dependent Claim
14 words
1 3. The process of claim 9 wherein, in the product, X is 1-indanyl.
Claim 14
Dependent Claim
30 words
The process of claim 9 wherein the product is one of the following: N-[1-Ethyoxycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-alanyl-proline. 2-N-[1-Ethoxycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-alanyl-l,2,3,4-tetrahydroisoquinoline-3-carboxylic acid. N-[N-[l-ethoxy-carbonyl-l-(2,3-dihydro-lH- inden-2-yl)-methyl]-alanyl]N-(2,3-Dihydro-1H-inden-5-yl)-glycine. N-[N-[1-ethoxycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-alanyl]N-Cyclopentyl-glycine. 1-N-[1-Ethoxycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-alanyl-2,3-dihydroindole-2-carboxylic acid. N-[(1S)-1-Ethoxycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-L-alanyl-L-proline. (3S)-2-N-[(1S)-1-Ethoxycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-L-alanyl-1,2,3,4-tetrahydroisoquinoline -3-carboxylic acid. N-[N-[(1S)-1-ethorycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-L-alanyl]N-(2,3-Dihydro-1H-inden-5-yl)-glycine. N-[N-[(lS)-l-ethoxycarbonyl-l-(2,3-dihydro-lH- inden-2-yl)-methyl]-L-alanyl]N-Cyclopentyl-glycine. (2S)-1-N-[(1S)-1-Ethoxycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl)-L-alanyl-2,3-dihydroindole-2-carboxylic acid.
Claim 15
Dependent Claim
22 words
A therapeutic composition comprising a therapeutically-effective amount of at least one compound produced by the process of any of claims 9 -14.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.